CA2666837C - Arylsulfonamide compounds - Google Patents

Arylsulfonamide compounds Download PDF

Info

Publication number
CA2666837C
CA2666837C CA2666837A CA2666837A CA2666837C CA 2666837 C CA2666837 C CA 2666837C CA 2666837 A CA2666837 A CA 2666837A CA 2666837 A CA2666837 A CA 2666837A CA 2666837 C CA2666837 C CA 2666837C
Authority
CA
Canada
Prior art keywords
compound
aryl
formula
heteroaryl
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2666837A
Other languages
English (en)
French (fr)
Other versions
CA2666837A1 (en
Inventor
Jonathan Bayldon Baell
Guillaume Laurent Lessene
Brad Edmund Sleebs
Wayne J. Fairbrother
John A. Flygare
Michael F. T. Koehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Genentech Inc
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research, Genentech Inc filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of CA2666837A1 publication Critical patent/CA2666837A1/en
Application granted granted Critical
Publication of CA2666837C publication Critical patent/CA2666837C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2666837A 2006-11-15 2007-11-15 Arylsulfonamide compounds Active CA2666837C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85931506P 2006-11-15 2006-11-15
US60/859,315 2006-11-15
PCT/US2007/084873 WO2008061208A2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Publications (2)

Publication Number Publication Date
CA2666837A1 CA2666837A1 (en) 2008-05-22
CA2666837C true CA2666837C (en) 2015-01-13

Family

ID=39276199

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2666837A Active CA2666837C (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Country Status (9)

Country Link
US (1) US8168645B2 (OSRAM)
EP (1) EP2094672B1 (OSRAM)
JP (1) JP5366817B2 (OSRAM)
CN (1) CN101535280B (OSRAM)
AU (1) AU2007319209B2 (OSRAM)
CA (1) CA2666837C (OSRAM)
ES (1) ES2423029T3 (OSRAM)
NZ (1) NZ577442A (OSRAM)
WO (1) WO2008061208A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
EA019156B1 (ru) 2008-02-01 2014-01-30 Такеда Фармасьютикал Компани Лимитед Производные оксима в качестве ингибиторов hsp90
US20110098305A1 (en) * 2008-05-21 2011-04-28 Jonathan Bayldon Baell Arylsulfonamide compounds, compositions and methods of use
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
MX2012003007A (es) * 2009-09-10 2012-04-11 Novartis Ag Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
BR112014014529A2 (pt) 2011-12-13 2019-09-24 Buck Inst For Res On Aging métodos para melhorar terapias médicas
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
AU2019207616A1 (en) 2018-01-10 2020-07-09 Recurium Ip Holdings, Llc Benzamide compounds
CN108276395B (zh) * 2018-02-09 2021-02-26 合肥华方医药科技有限公司 一种多沙唑嗪杂质的制备方法
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
MXPA04009141A (es) * 2002-03-21 2004-11-26 Abbott Lab Promotores de apoptosis, de n-sulfonilurea.
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
JP4826256B2 (ja) 2003-11-20 2011-11-30 三菱瓦斯化学株式会社 液状シクロヘキサントリカルボン酸無水物
WO2005117543A2 (en) * 2004-05-26 2005-12-15 Abbott Laboratories N-sulfonylcarboximidamide apoptosis promoters
KR20070046180A (ko) * 2004-08-20 2007-05-02 더 리젠츠 오브 더 유니버시티 오브 미시간 항세포사멸 ｂｃｌ-2군 구성원의 소분자 억제제 및 이의용도
US20060122247A1 (en) * 2004-12-08 2006-06-08 Solvay Pharmaceuticals B.V. Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
DK1888550T3 (da) * 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer

Also Published As

Publication number Publication date
EP2094672A2 (en) 2009-09-02
EP2094672B1 (en) 2013-05-29
ES2423029T3 (es) 2013-09-17
US8168645B2 (en) 2012-05-01
CN101535280A (zh) 2009-09-16
CN101535280B (zh) 2012-06-27
WO2008061208A2 (en) 2008-05-22
CA2666837A1 (en) 2008-05-22
HK1134283A1 (en) 2010-04-23
NZ577442A (en) 2012-02-24
JP2010510237A (ja) 2010-04-02
AU2007319209B2 (en) 2012-04-19
JP5366817B2 (ja) 2013-12-11
WO2008061208A3 (en) 2008-07-03
AU2007319209A1 (en) 2008-05-22
US20100056517A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
CA2666837C (en) Arylsulfonamide compounds
ES2967983T3 (es) Compuestos
US7432377B2 (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
US20100197711A1 (en) Benzothiazole compounds
WO2017101803A1 (zh) 一种新型egfr和alk激酶的双重抑制剂
AU2019218187B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
TW201418220A (zh) 新的喹啉類化合物及其用途
Altıntop et al. Synthesis and evaluation of a series of 1, 3, 4-thiadiazole derivatives as potential anticancer agents
CN105829285A (zh) 喹唑啉酮和异喹啉酮衍生物
CA2871453A1 (en) Quinazolinedione derivative
CN113924288B (zh) 一种含喹啉基化合物、药物组合物以及其用途
EP3388428B1 (en) Five-membered heterocyclic amides wnt pathway inhibitor
CN111303121A (zh) 含喹喔啉酮的4-苯氧基吡啶类化合物及其应用
CN106478606A (zh) N‑取代吲哚类衍生物及其应用
JP7190755B2 (ja) オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用
JP7022454B2 (ja) ジオキシノキノリン系化合物、その調製方法および使用
HK1134283B (en) Arylsulfonamide compounds
CN111440177B (zh) 一种取代吡唑并[1,5-a]嘧啶类化合物及其制备方法和应用
WO2025010279A2 (en) Polo-like kinase 1 inhibitors
HK40042713A (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
HK40042713B (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof

Legal Events

Date Code Title Description
EEER Examination request